The potential impact of a moderately effective HIV vaccine with rapidly waning protection in South Africa and Thailand

Vaccine

Volumn 29, Issue 36, 2011, Pages 6092-6099

  Andersson, Kyeen M ^a   Stover, John ^a  

^a AVENIR HEALTH   (United States)

Author keywords

Combination prevention; HIV prevention; HIV vaccine; Mathematical model; South Africa; Thailand

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS VACCINE; RV144; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CLINICAL TRIAL (TOPIC); DRUG EFFICACY; FEMALE; HEALTH PROGRAM; HIGH RISK POPULATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; INFECTION PREVENTION; MAJOR CLINICAL STUDY; MALE; MATHEMATICAL MODEL; PRIORITY JOURNAL; SOUTH AFRICA; THAILAND; VACCINATION;

ADOLESCENT; ADULT; AIDS VACCINES; CLINICAL TRIALS AS TOPIC; COMPUTER SIMULATION; FEMALE; HIV; HIV INFECTIONS; HUMANS; IMMUNIZATION PROGRAMS; MALE; MIDDLE AGED; MODELS, THEORETICAL; SEX WORKERS; SOUTH AFRICA; THAILAND; TIME FACTORS; TREATMENT OUTCOME; VACCINATION; YOUNG ADULT;

EID: 80051471567     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.06.060     Document Type: Article

References (15)

1. Global report: UNAIDS report on the global AIDS epidemic 2010. Geneva: Joint United Nations Programme on HIV/AIDS; 2010.
2. McCormack S., Ramjee G., Kamali A., Rees H., Crook A., Gafos M., et al. PRO2000 vaginal gel for prevention of HIV-1 infection (Microbicides Development Programme 301): a phase 3, randomised, double-blind, parallel-group trial. Lancet 2010, 376:1329-1337.
3. Grant R.M., Lama J.R., Anderson P.L., McMahan V., Liu A.Y., Vargas L., et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med 2010, 363:2587-2599.
4. Abdool Karim Q., Abdool Karim S.S., Frohlich J.A., Grobler A.C., Baxter C., Mansoor L.E., et al. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science 2010, 329:1168-1174.
5. Francis D.P., Heyward W.L., Popovic V., Orozco-Cronin P., Orelind K., Gee C., et al. Candidate HIV/AIDS vaccines: lessons learned from the world's first phase III efficacy trials. AIDS 2003, 17:147-156.
6. Database of AIDS vaccine candidates in clinical trials. New York: International AIDS Vaccine Initiative. Available at ; accessed February 13, 2011. http://www.iavireport.org/trials-db/Pages/default.aspx.
7. Rerks-Ngarm S., Pitisuttithum P., Nitayaphan S., Kaewkungwal J., Chiu J., Paris R., et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med 2009, 361:2209-2220.
8. Hankins C, Macklin R, Michael N, Stablein D, and the participants at the March meeting in Bangkok Thailand. Recommendations for the future utility of the RV144 vaccines to the Thai Ministry of Health: Report on meeting in Bangkok, Thailand March 16-18, 2010. Bangkok: Global HIV Vaccine Enterprise, WHO-UNAIDS, Thai Ministry of Public Health, and U.S. Military HIV Research Program; 2010. Available at ; accessed February 14, 2011. http://www.vaccineenterprise.org/sites/default/files/RV144_March16-18_Meeting_Report_FINAL.pdf.
9. Bollinger L, Stover J. HIV vaccine: A model for examining the effects of an HIV vaccine. Glastonbury, CT: Futures Institute; July 2006. Available at ; accessed February 12, 2011. http://futuresinstitute.org/Download/Spectrum/Manuals/Vaccine%20Manual.pdf.
10. Stover J., Bollinger L., Hecht R., Williams C., Roca E. The impact of an AIDS vaccine in developing countries: a new model and initial results. Health Aff 2007, 26:1147-1158.
11. Fonseca M.G.P., Forsythe S., Menezes A., Vuthoori S., Possas C., Veloso V., et al. Modeling HIV vaccines in Brazil: assessing the impact of a future HIV vaccine on reducing new infections, mortality and number of people receiving ARV. PLoS ONE 2010, 5:e11736.
12. Uganda: Estimating the potential impact of an AIDS vaccine. Policy Brief 23. New York: International AIDS Vaccine Initiative; August, 2009. Available at ; accessed February 12, 2011. http://www.iavi.org/publications-resources/Pages/PublicationDetail.aspx?pubID=454d7f8e-f58a-4bf0-9694-36447fa52211.
13. Kenya: Estimating the potential impact of an AIDS vaccine. Policy Brief 24. New York: International AIDS Vaccine Initiative; December, 2009. Available at ; accessed February 12, 2011. http://www.iavi.org/publications-resources/Pages/PublicationDetail.aspx?pubID=3f762fb5-38f1-4e84-b1ea-61eacc257417.
14. Hecht R., Stover J., Bollinger L., Muhib F., Case K., de Ferranti D. Financing of HIV/AIDS programme scale-up in low-income and middle-income countries, 2009-31. Lancet 2010, 376:1254-1260.
15. Bollinger L, Stover J, Forsythe S. Estimating long-term global resource needs for AIDS through 2031. Glastonbury, CT: Results for Development Institute, Futures Institute, and the aids2031 Costs and Financing Working Group; 2009. Available at ; accessed February 14, 2011. http://www.resultsfordevelopment.org/publications/estimating-long-term-global-resource-needs-aids-through-2031.